ACM
KERX

Asymmetry Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Asymmetry Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-68,381
Closed -$421K – 37
2017
Q1 		$421K Buy
+68,381
New +$375K 0.59% 25

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Asymmetry Capital Management's KERX Position: Q2 2017 in Review

Asymmetry Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2017, closing a stake of 68,381 shares — an estimated $421K sold.

Asymmetry Capital Management first reported a position in KERX in Q1 2017 and held it in 1 quarter. The position peaked at $421K in Q1 2017. 126 funds tracked by Wall St. Rank hold KERX as of Q2 2017.

  • Asymmetry Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • Asymmetry Capital Management sold 68,381 Keryx Biopharmaceuticals Inc shares in Q2 2017, an estimated $421K.
  • Asymmetry Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q1 2017 and held it in 1 quarter.
  • Asymmetry Capital Management's Keryx Biopharmaceuticals Inc position peaked at $421K in Q1 2017.
  • 126 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2017.

Based on Asymmetry Capital Management's 13F filing for Q2 2017, filed 15 Aug 2017.